On January 30, 2025 Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, reported that members of management will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on February 6, 2025 at 1:30 p.m. ET (Press release, Mersana Therapeutics, JAN 30, 2025, View Source [SID1234649961]). A live webcast of this event will be available on the Investors & Media section of Mersana’s website at www.mersana.com, and an archived replay will be available for approximately 90 days following the event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!